Remember meForgot password?
    Log in with Twitter
Press Release

CRISPR Market by Product, Service, End User, Worth $550.0 Mn by 2030: Top Key Players - CRISPR THERAPEUTICS, Mirus Bio LLC, Takara Bio USA, Editas Medicine

The CRISPR technology is focused on development or growth of the gene therapeutics for the treatment of several genetic disorders including hemophilia, thalassemia, and sickle cell anemia, among others. The growing prevalence of hereditary disorders is promoting the growth of the market, for improved treatment and better quality of life for patients.

This press release was orginally distributed by SBWire

New York, NY -- (SBWIRE) -- 03/14/2019 -- CRISPR Market and Patent Landscape Report by Applications (academic research tools, drug development, agriculture, human clinical therapeutics, and animal and disease model), by Products (editing tools, cell lines, animal models and plant breeding products), by Technology (drug compound and target screening, and agriculture and industrial use), by Patent Activities (patent categories and classification, leading patent players, technical analysis of patent landscape, patent licensing and litigation) – Global Forecast, 2030.

Market Industry Reports (MIR) has published a new report titled "CRISPR Technology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2030." According to the report, the global CRISPR technology market was valued at over US$ 550.0 Mn in 2017 and is expected to grow at a double digit CAGR during the forecasted period.
This report focuses on the CRISPR-Cas9 genome editing tools including its technology, market, and patent landscape. The report forecasts the sizes and trends of the global market as well as its sub-segments for the period 2019 to 2030. The report focuses on critical market segments to identify the key market and technology trends. Market driving factors and constraints have been considered to estimate global CRISPR market potential.

Request Free sample Copy @

Patent trends have been presented in detail to understand the research and development activities happening around the world over the years. The study also delves into licensing and litigation battles which are restricting the commercial growth of the market. The report will also present a competitive landscape focusing on active players in the industry, growth strategies, strategic imperatives and detailed profiling of critical companies.

Get your analysis on 150 page up to date report and detailed TOC on CRISPR Market – Patent landscape report.

Key players are looking for licensing with the other companies

The key players operating in the global CRISPR technology market include Addgene, Caribou Biosciences, Inc., Merck KGaA, Horizon Discovery Group plc,CRISPR THERAPEUTICS, Mirus Bio LLC, Takara Bio USA, Editas Medicine, Thermo Fisher Scientific, Inc., GE Healthcare Dharmacon Inc. and Intellia Therapeutics, Inc. Companies are involved in collaborations to gain share in the market.For instance, Caribou Biosciences develop CRISPR technology in collaboration with the research based on University of California.

The application segment is expected to grow by four times of its market size of $156 million in 2017 to $609 million in 2030. CRISPR-Cas9 tools will play a multifarious role in agriculture by enabling the industry in editing crops to make them more nutritious, enhanced taste, disease resistant, and less susceptible to drought. Agriculture and plant breeding application segment is restricted in growth by several potential regulatory requirements and ethical apprehensions.

Get the most relevant, personalized intelligence for CRISPR-Cas9 market to make your company grow and succeed.

Top leading players and the geographic regions

The three leading players in the CRISPR field are Intellia Therapeutics, CRISPR Therapeutics, and Editas Medicine established by CRISPR pioneers has achieved billion-dollar market capitalization and are focused on the clinical as well as non-clinical applications of CRISPR-Cas9 technology. Large biotech companies and pharmaceuticals like Novartis, Vertex, Bayer AG have skin in the CRISPR game exploring novel techniques to evolve their drug discovery and development processes, and forming strategic alliances with crucial CRISPR technology companies to devise gene-based therapies for various genetic diseases.

The North American market has the maximum number of companies dealing with CRISPR-Cas9 products or services. About 64 per cent of the top companies with business related to CRISPR-Cas9 gene editing are in the U.S or Canada. The U.S. market is leading in the field regarding the number of companies involved in genome editing.
Novel treatments for single-gene disorders such as cystic fibrosis, haemophilia and sickle cell disease are being researched using Cas9 tools.

This technique is anticipated to be useful in the prevention and cure of complex conditions, such as cancer, heart disease, mental illness, and human immunodeficiency virus (HIV) infection. Research and Development investment in the technology is growing by leaps and bounds, the technology's potential has been explored in newer areas of animal and disease model development, drug compound and target screening, and agriculture and nutritional health products.

Clinical therapy segment is the leading focus area of R&D with 482 patent applications

The North American market lead the industry in 2017 with $504 million followed by Europe at $340 million and APAC closely behind at $325 million. The Chinese government is heavily committed to CRISPR research and has awarded more than 23 million yuan ($3.5 million) to 42 CRISPR projects. With an eight-year CAGR of 19.77 per cent, the North America market is predicted to continue dominating the global markets by 2030. APAC market is presumed to assume second position in the global markets with 3.96 per cent higher market share that European market in 2030. Rapid growth in the Rest of World (RoW) market is also expected.

A complex licensing model has sprouted around the pioneering IP portfolio.

All the CRISPR patent holders and institutes associated with them have set up companies to commercialize the patents by sublicensing them for therapeutic, agriculture and many other application areas to biotech firms, pharmaceuticals, agri-businesses etc. Caribou Biosciences, ERS Genomics, Editas Medicine, Intellia Therapeutics, and CRISPR Therapeutics are the spin offs associated with CRSIPR landscape. Not many large scale commercial assignees have actively participated in the early phases of the CRISPR–Cas patent landscape. The only large establishments making it to the top ten are Dow AgroSciences and DuPont Nutrition Science (now merged as DowDuPont), together holding 20 inventions in CRISPR-Cas9 applications in agriculture and animal biotechnology.

Ask For Inquiry before Buying@

About Market Industry Reports
Market Industry Reports is a global leader in market measurement & advisory services, Market Industry Reports is at the forefront of innovation to address the worldwide industry trends and opportunities. We identified the caliber of market dynamics & hence we excel in the areas of innovation and optimization, integrity, curiosity, customer and brand experience, and strategic business intelligence through our research.

We continue to pioneer state-of-the-art approach in research & analysis that makes complex world simpler to stay ahead of the curve. By nurturing the perception of genius and optimized market intelligence we bring proficient contingency to our clients in the evolving world of technologies, megatrends and industry convergence. We empower and inspire Vanguards to fuel and shape their business to build and grow world-class consumer products.

Contact Us- 

502, Sai Radhe, Kennedy Road,
Behind Hotel Sheraton Grand,
Near Pune Station, Pune 411 001
Phone: + 91 8956 767 535
Follow Us- LinkedIn | Twitter | Google+ | Facebook

For more information on this press release visit:

Media Relations Contact

Veena Kumari
Telephone: +918956767535
Email: Click to Email Veena Kumari

Latest News
Top News